Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update
Link to Full Article Company earns $750,000 milestone payment related to SWARM-P.a. Study MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided […]